Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13902805 | 0.81 | PTGER1 (0.60) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13902810 | 0.81 | PTGER1 (0.60) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13239376 | 0.80 | PTGER1 (0.80) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13902807 | 0.77 | PTGER1 (0.61) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL25113757 | 0.76 | PTGER1 (0.63) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL2956473 | 0.76 | PTGER1 (0.62) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13239372 | 0.74 | PTGER1 (0.76) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL2954536 | 0.73 | PTGER1 (0.70) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL4152215 | 0.73 | PTGER1 (1.00) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13902798 | 0.72 | PTGER1 (0.50) | PTGER1CYP1A2CYP2C9TBXA2RPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833795-B1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2009-03-04 | — | — | EP | disclosed |